

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A method for inhibition of initiation of primary or metastatic tumor growth tumorigenesis in an individual suffering from or at risk for a tumor type that expresses a6b4 integrin, comprising the steps of administering to the individual a therapeutic agent effective to reduce the amount of active a6b4 integrin at least in a portion of the individual where initiation of primary or metastatic tumor growth tumorigenesis may occur by targeting the beta 4 portion of the integrin.
2. (original) The method of claim 1, wherein the individual is human.
3. (currently amended) The method of claim 1 or 2, wherein the therapeutic agent is an antibody.
4. (currently amended) The method of claim 1 or 2, wherein the therapeutic agent is an antisense oligonucleotide.
5. (currently amended) The method of claim 1 or 2, wherein the therapeutic agent is an RNAi species.
6. (currently amended) The method of claim 2 any one of claims 1 to 5, wherein the individual is suffering from or at risk for a tumor type selected from the group consisting of thyroid; breast; and prostate and cervical cancers, cancer of the upper gastrointestinal tract and squamous carcinoma of the skin.
7. (currently amended) The method of any of claims 1 to 6, further comprising the step of administering to the individual an inhibitor of a receptor protein tyrosine kinase such as ErbB2, EGF-R, Met and Ron.

8-12. (canceled)

13. (new) The method of claim 7, wherein the receptor protein tyrosine kinase is selected from the group consisting of ErbB2, EGF-R, Met and Ron.

14. (new) The method of claim 2, further comprising the step of administering to the individual an inhibitor of a receptor protein tyrosine kinase.

15. (new) The method of claim 14, wherein the receptor protein tyrosine kinase is selected from the group consisting of ErbB2, EGF-R, Met and Ron.

16. (new) A method for inhibition of initiation of primary or metastatic tumor growth in an individual suffering from or at risk for a tumor type that expresses a6b4 integrin, comprising administering to the individual a therapeutic agent effective to reduce the amount of active a6b4 integrin at least in a portion of the individual where initiation of primary or metastatic tumor growth may occur by targeting the beta 4 portion of the integrin, wherein the tumor expresses an amplified or activated version of a receptor protein kinase.

17. (new) The method of claim 16, wherein the receptor protein kinase is selected from the group consisting of erbB2, EGF-R, Met and Ron.

18. (new) The method of claim 16, wherein the individual is human.

19. (new) The method of claim 18, wherein the tumor is breast cancer or prostate cancer.

20. (new) The method of claim 18, wherein the therapeutic agent is an antibody.

21. (new) The method of claim 18, wherein the therapeutic agent is an antisense oligonucleotide.

22. (new) The method of claim 18, wherein the therapeutic agent is an RNAi species.
23. (new) The method of claim 18, further comprising the step of administering to the individual an inhibitor of a receptor protein tyrosine kinase.
24. (new) The method of claim 23, wherein the receptor protein tyrosine kinase is selected from the group consisting of erbB2, EGF-R, Met and Ron.